A Drug Release Model Constructed by Factorial Design to Investigate the Interaction Between Host Mesoporous Silica Carriers and Drug Molecules

被引:5
作者
Liu, Tong [1 ,2 ]
Wang, Keke [1 ,2 ]
Jiang, Mingyan [1 ,2 ]
Wan, Long [1 ,2 ]
机构
[1] China Med Univ, Hosp 1, Dept Pharm, 155 Nanjing North St, Shenyang 110001, Liaoning, Peoples R China
[2] China Med Univ, Sch Pharm, 77 Puhe Rd, Shenyang 110122, Liaoning, Peoples R China
基金
中国国家自然科学基金;
关键词
mesocellular foam silica; factorial design; drug release; MESOCELLULAR FOAM; IN-VITRO; ORAL BIOAVAILABILITY; DELIVERY SYSTEM; PORE-SIZE; NANOPARTICLES; WATER; ADSORPTION; CHITOSAN; OPTIMIZATION;
D O I
10.1208/s12249-019-1340-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A drug release model based on mesocellular foam silica (MCF) for Biopharmaceutics Classification System (BCS) II drugs was conducted. A three-level two-factorial factorial design was carried out for the exploration of the influence of the pore size of MCF (X-1) and drug-loading degree (X-2) for drug release behaviors. Cumulative release in 1h (Y-1), cumulative release in 24h (Y-2), and rate constant k (Y-3) were selected as dependent response variables. A series of MCFs (7MCF, 12MCF, and 17MCF) with arithmetic increased pore diameters was synthesized as drug carriers. The morphologies and structures of MCFs and pore size distributions were detected by scanning electron microscopy, transmission electron microscopy, and nitrogen adsorption analysis. With celecoxib as a model drug, nine drug-loaded samples were prepared and further characterized by differential scanning calorimetry and X-ray diffraction analyses. The release behavior was examined by in vitro dissolution. Factorial design results demonstrated that cumulative release in 1h and the rate constant k were mainly affected by X-2, while cumulative release in 24h was influenced by both X-1 and X-2. Furthermore, quadratic equations of Y-1, Y-2, and Y-3 were conducted, respectively. This work was expected to provide some scientific references for designing specific drug delivery models with mesoporous silica carrier.
引用
收藏
页数:9
相关论文
共 52 条
[11]   Development of Duloxetine Hydrochloride Loaded Mesoporous Silica Nanoparticles: Characterizations and In Vitro Evaluation [J].
Ganesh, Mani ;
Ubaidulla, Udhumansha ;
Hemalatha, Pushparaj ;
Peng, Mei Mei ;
Jang, Hyun Tae .
AAPS PHARMSCITECH, 2015, 16 (04) :944-951
[12]   Mesoporous-Silica-Functionalized Nanoparticles for Drug Delivery [J].
Giret, Simon ;
Man, Michel Wong Chi ;
Carcel, Carole .
CHEMISTRY-A EUROPEAN JOURNAL, 2015, 21 (40) :13850-13865
[13]   Manipulating Crystal Growth and Polymorphism by Confinement in Nanoscale Crystallization Chambers [J].
Hamilton, Benjamin D. ;
Ha, Jeong-Myeong ;
Hillmyer, Marc A. ;
Ward, Michael D. .
ACCOUNTS OF CHEMICAL RESEARCH, 2012, 45 (03) :414-423
[14]   Antibacterial and anti-inflammatory drug delivery properties on cotton fabric using betamethasone-loaded mesoporous silica particles stabilized with chitosan and silicone softener [J].
Hashemikia, Samaneh ;
Hemmatinejad, Nahid ;
Ahmadi, Ebrahim ;
Montazer, Majid .
DRUG DELIVERY, 2016, 23 (08) :2946-2955
[15]   Facile synthesis of 3D cubic mesoporous silica microspheres with a controllable pore size and their application for improved delivery of a water-insoluble drug [J].
Hu, Yanchen ;
Wang, Jing ;
Zhi, Zhuangzhi ;
Jiang, Tongying ;
Wang, Siling .
JOURNAL OF COLLOID AND INTERFACE SCIENCE, 2011, 363 (01) :410-417
[16]   Dodecylamine Template-Based Hexagonal Mesoporous Silica (HMS) as a Carrier for Improved Oral Delivery of Fenofibrate [J].
Jadhav, Nitin V. ;
Vavia, Pradeep R. .
AAPS PHARMSCITECH, 2017, 18 (07) :2764-2773
[17]   Stabilization and Amorphization of Lovastatin Using Different Types of Silica [J].
Khanfar, Mai ;
Al-Nimry, Suhair .
AAPS PHARMSCITECH, 2017, 18 (06) :2358-2367
[18]   Application of response surface methodology (RSM) for the removal of methylene blue dye from water by nano zero-valent iron (NZVI) [J].
Khosravi, Morteza ;
Arabi, Simin .
WATER SCIENCE AND TECHNOLOGY, 2016, 74 (02) :343-352
[19]   Full factorial design for optimization, development and validation of HPLC method to determine valsartan in nanoparticles [J].
Kumar, Lalit ;
Reddy, M. Sreenivasa ;
Managuli, Renuka S. ;
Pai, Girish K. .
SAUDI PHARMACEUTICAL JOURNAL, 2015, 23 (05) :549-555
[20]   Enhanced oral delivery of celecoxib via the development of a supersaturable amorphous formulation utilising mesoporous silica and co-loaded HPMCAS [J].
Laine, A. -L. ;
Price, D. ;
Davis, J. ;
Roberts, D. ;
Hudson, R. ;
Back, K. ;
Bungay, P. ;
Flanagan, N. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2016, 512 (01) :118-125